Those include high blood pressure, high cholesterol, sleep apnea and joint pain
(30) However, they had higher odds of myocardial infarction (1.0% vs
However, there are still many controversies regarding the tolerability and adverse reactions of GLP-1RAs in the treatment of diabetes
These drugs vary, like changing pharmacokinetics, and different drugs have different dose plans for daily or weekly injections (139)
Double Incretin Receptor Knockout (DIRKO) Mice DIRKO mice have normal body weight and do not have improved glycaemic response following exogenous administration of GIP or the GLP-1R agonist exendin-4
Cardiovascular Outcome Trials in Type 2 Diabetes CVOTs in T2D were designed primarily to establish cardiovascular safety in patients diagnosed with T2D who also have established cardiovascular disease (CVD) or have a high cardiovascular risk